- Home
- SHMD vs NBP Comparison
SHMD vs NBP Comparison
Compare SHMD & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | NBP |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 205.9M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHMD | NBP |
|---|---|---|
| Price | $2.98 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.3M | 645.2K |
| Earning Date | 11-25-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.82 | N/A |
| Revenue Next Year | $36.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.93 | $1.26 |
| 52 Week High | $10.65 | $5.19 |
Technical Indicators
Market Signals| Indicator | SHMD | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 32.62 |
| Support Level | N/A | N/A |
| Resistance Level | $3.65 | $1.44 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 3.23 | 27.11 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.